| Objective:To observe the clinical efficacy of Shenqifuzheng injection in acute exacerbation of chronic respiratory failure (Qi phlegm syndrome) and explore its mechanism.Methods:According to randomized, controlled principle,60 patients were divided into test group of 30 and control group of 30. Test group received the standard treatment in proprietary formulations Shenqifuzheng plus 250ml intravenous injection once a day based on conventional medicine. Conventional medicine was given to the control group. Comprehensive after treatment were observed effect, the death toll, the average length of stay, time to achieve therapeutic goals, and hematology parameters, blood gas analysis, FEV1%, ventilator-associated targets and adverse effects. Results:Both the integrated effect of the number of deaths was no significant difference (P>0.05), but compared with the control group, the average length of stay (P<0.05), time to achieve the target effect(P<0.01) of the test group were significantly shorter, efficacy Syndrome Evaluation (P<0.01)of the test group was better, blood parameters normalization condition (P<0.05), the result of the arterial blood gas analysis (P<0.01)and the improvement of FEV1%(P<0.01) expressed by test group were better, the number of people need to apply the ventilator, ventilator-associated pneumonia and the number of offline days of the test group were less than the control group.Conclusion:Injection Shenqifuzheng acute exacerbation of chronic respiratory failure can significantly improve the clinical symptoms, regulating immunity, and combined with conventional treatment, it can help control the infection, speed up the condition improved, increase the effective length of hospital stay, in theory and control can reduce the chance of complications caused by ventilator. The mechanism may be that Shenqifuzheng injection can increase immunity, improved diaphragmatic fatigue and respiratory function, anti-inflammatory and anti-bacterial. |
PDF Full Text Request